Drug Profile
Research programme: therapeutic antibodies - Adimab/Biogen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Adimab; Biogen Idec
- Developer Adimab; Biogen
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified